Bispecific Antibodies in the Treatment of Multiple Myeloma: An Expert Case-Based Discussion

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.

Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.

Closing out their module on BCMA-targeted therapy in relapsed/refractory MM, panelists highlight the optimal management of ICANS and infections.

Switching focus to GPRC5-targeted bispecific antibody therapy, expert hematologist-oncologists review a patient case of relapsed/refractory MM managed with talquetamab.

Considerations for the integration of GPRC5-targeted therapy into the real-world treatment paradigm of relapsed/refractory multiple myeloma.

Centering discussion on the final patient case, experts review the case of a patient with relapsed/refractory multiple myeloma managed with FcRH5-targeting bispecific cevostamab.

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.

A panel of experts reviews how the recent approval of teclistamab, a bispecific antibody, has changed the treatment landscape for patients with multiple myeloma.